The US 340B program requires drugmakers to provide certain medications at a significant discount to safety-net care centers that provide care for patients in economically disadvantaged areas through Medicaid and Medicare Part B. In a new BenefitsPRO interview with Sarah Hearn of RxBenefits, learn how the 340B program has impacted manufacturers and commercial payers.
According to Hearn, “Savings generated through 340B allow safety-net institutions to carry out incredibly meaningful programs, such as funding free and low-cost medications, dental and primary care clinics that serve our most vulnerable citizens, as well as research into HIV/AIDS, diabetes, and cancer. It is also important to remember that none of these 340B savings provided to eligible health care institutions are taxpayer funded. One hundred percent of 340B savings are funded by Pharma which is mandated to offer these savings to sell their drugs to Medicare and Medicaid.”
To read more, click here.
(Source: BenefitsPRO, May 18th, 2023)